| Document |
Document Title |
|
WO/2006/052263A1 |
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropy...
|
|
WO/2006/047022A1 |
The sulfated oxysterol 5-cholesten-3β, 25-diol 3-sulphate, a nuclear steroid metabolite that increases cholesterol secretion and degradation, is provided as an agent to lower intracellular and serum cholesterol. Methods which involve th...
|
|
WO/2006/045745A1 |
A process is described for preparing, exclusively by chemical way, 21-hydroxy steroids having progestinic activity, said process having a high stereochemical control at C-21 position.
|
|
WO/2006/024296A1 |
The present invention relates to processes for epimerising alcohols of compounds having a hydroxyl substituent on an asymmetric allylic carbon, such as compounds useful for the synthesis of vitamin D analogues where the epimeric hydroxyl...
|
|
WO/2006/018019A2 |
The invention relates to an inhibitor of 11ß hydroxysteroid dehydrogenase (11ß-HSD), which exclusively inhibits 11ß hydroxysteroid dehydrogenase type 1, but not 11ß hydroxysteroid dehydrogenase type 2.
|
|
WO/2006/010307A1 |
A synthetic method of 20 (s)-ginsenoside Rh2, i. e. 20(S)-protopanaxdiol - 3 - 0 - β - D - glucopyranoside, comprising: selectively protecting protopanaxadiol first to afford monosubstituted protopanaxadiol, and Glycosidating the monosu...
|
|
WO/2006/006718A1 |
The invention aims at providing a novel process for the production of steroids. The invention provides a process for the production of 5β-3,7-dioxocholanoic acid or esters thereof from a starting sterol having double bonds at the 5- and...
|
|
WO/2006/004030A1 |
A pharmaceutical having the potency of inhibiting the production of tissue factors, which pharmaceutical comprises an LXR ligand as an active ingredient. There is provided a pharmaceutical for the treatment and/or prevention of vascular ...
|
|
WO/2005/116048A1 |
Process for the recovery of sterols from organic material, which comprises a) reacting the organic material containing free sterols and sterol derivatives with (i) polyols or (ii) polyamines or (iii) alkanolamines or (iv) alcohols to lib...
|
|
WO/2005/095435A1 |
A method for producing a pregnane derivative is characterized by the process wherein a pregnane derivative represented by the general formula (II) below is produced by silylating a compound represented by the formula (I) below using a si...
|
|
WO/2005/094838A1 |
Compounds having effects of ameliorating hyperglycemia and lowering hemoglobin Alc level such as 4-methylcholest-7-en-3-ol, 4-methylergost-7-en-3-ol and 4-methylstigmast-7-en-3-ol are employed as the active ingredient of drugs, foods or ...
|
|
WO/2005/090379A1 |
Compound for binding an electron deficient polycyclic aromatic hydrocarbon (PAH) comprising a 'tweezer' of formula I: wherein is any C15-45 planar skeleton comprised of a saturated fused alicyclic (3) to (8) ring system each X is a linki...
|
|
WO/2005/082925A2 |
The invention relates to a FXR agonist of formula (I) and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
|
|
WO/2005/079164A2 |
It is intended to provide 5&agr -reductase inhibitors efficacious in preventing and treating diseases in which androgen participates, for example, prostatic cancer, prostatic hypertrophy, male pattern alopecia, simple acne, seborrhea and...
|
|
WO/2005/070435A1 |
It is intended to provide an agent for improving dynamic eyesight by which dynamic eyesight can be effectively improved. Namely, an agent for improving dynamic eyesight which comprises, as the active ingredient, a Bacopa monniera extract...
|
|
WO/2005/070949A1 |
The present invention is a di-steroidal prodrug of estradiol having formula (I).
|
|
WO/2005/058934A2 |
The present invention relates to novel glycosylated steroid compounds having anti-migratory activity. The present invention also relates to a method for the preparation of said glycosylated steroid compounds. The invention further relate...
|
|
WO/2005/049037A1 |
The invention relates to a process for producing a substantially stable dispersion without manufacturing aids, where the dispersion comprises at least one hydrophobic plant sterol and an aqueous material, wherein the plant sterol is sele...
|
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2005/026189A1 |
Disclosed is a process for the recovery of a phytolipid composition from a vegetable oil by-product. The phytolipid composition produced comprises squalene, phytosterols, mixed tocopherols and tocotrieneols, and vegetable wax and is usef...
|
|
WO/2005/023832A1 |
The present invention includes a compound which combines, through esterification, the natural cholesterol lowering properties of plant sterols or stanols with the natural cholesterol lowering properties of fatty acids, more particularly ...
|
|
WO/2005/023831A1 |
The invention relates to detection of cholesterol ozonation products that are generated by atherosclerotic plaque material, and to methods of detecting vascular conditions that relate to the accumulation and oxidation of cholesterol.
|
|
WO/2005/023830A2 |
As illustrated herein, cholesterol is oxidized when it is present in atherosclerotic plaques. This reaction generates cytotoxic cholesterol oxidation or ozonation products. The present application is directed to the products of cholester...
|
|
WO/2005/009361A2 |
This invention relates to the improved methods of use of Argatroban in heparin-induced thombocytopenia.
|
|
WO/2005/007669A1 |
The present Invention relates to novel fusidic acid derivatives of general formula (I) wherein X represents halogen, trifluoromethyl, cyano, azido, alkyl, alkenyl or aryl, wherein. said alkyl, alkenyl or aryl are optionally substituted b...
|
|
WO/2005/005453A2 |
The present invention provides, in one aspect, novel compounds comprising sterols and/or stanols and cholesterol biosynthesis inhibitors, including salts of these compounds and solvates and prodrugs of these compounds and/or salts. In an...
|
|
WO/2005/000866A1 |
New cyclopentaperhydrophenathrene salts 3-β-carboxylic acid salts for preparing oil/water emulsions for dermatological, cosmetic and pharmaceutical use, obtained by reaction of products of natural origin, preferably sitosterols. With re...
|
|
WO/2004/111073A2 |
The aim of the invention is to use a product resulting from the processing of oleaginous vegetable compounds for sterol recovering. The aim of said invention also is a method for recovering sterols contained in the oils of the oleaginous...
|
|
WO/2004/096232A1 |
An interleukin-8 enhancer which comprises dehydroepiandrosterone sulfate or a pharmaceutically acceptable salt thereof as the active ingredient. This enhancer activates interleukin-8 receptors and increases the number of interleukin rece...
|
|
WO/2004/092193A1 |
Process for preparing ursodeoxycholic acid di-sodium 3,7-disulfate comprising: a) reacting ursodeoxycholic acid with sulfamic acid to give ursodeoxycholic acid di-ammonium 3,7-disulfate; b) treating ursodeoxycholic acid di-ammonium 3,7-d...
|
|
WO/2004/091474A2 |
The invention relates to a method for the production of DHEA derivatives, such as 7-oxo-DHEA and 7-hydroxy-DHEA, from DHEA itself.
|
|
WO/2004/089969A2 |
Unique compounds that can be used for inducing an immune response to Borrelia burgdorferi in a subject by administering a therapeutically effective amount of the glycolipid to the subject. Such administration is particularly useful for p...
|
|
WO/2004/082581A2 |
The invention relates to a compound having formula (I), wherein: X = O or group = N-OH; R represents a group selected from R1, R2, R3, R4, R6, R5; A = hydrogen or, together with B, a carbon-carbon linkage; B = hydrogen, hydroxy or, toget...
|
|
WO/2004/082631A2 |
A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of l&agr ,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxi...
|
|
WO/2004/083229A1 |
The invention relates to a novel sterol and/or stanol ester of ethercarboxylic acid of general formula (I): R (OAlk)n OCH2COOH, wherein R is an alcohol derivative alkyl alcenyl and/or alkylphenyl group comprising 1-50 carbon atoms, OAlk ...
|
|
WO/2004/065358A2 |
A method of minimizing or reducing the toxicity of a retinoid having a free carboxyl group is described. The method comprises the step of esterifying the carboxyl group of the retinoid with a highly sterically hindered alcohol. The resul...
|
|
WO/2004/064743A2 |
A method of minimizing or reducing the toxicity of a retinoid having a free carboxyl group and the resulting modified retinoids are described. The method comprises the step of esterifying the carboxyl group of the retinoid with a highly ...
|
|
WO/2004/057013A1 |
A process for producing 7&agr -hydroxypregn-4-en-3-one-20-carbaldehyde, characterized in that a microorganism which belongs to the genus Alcaligenes and acts on 3&agr ,7&agr -dihydroxy-5ß-cholanic acid and/or a salt thereof as a substra...
|
|
WO/2004/055039A1 |
The present invention relates to novel steroid compounds of Formula (IB) having anti-tumor activity. The present invention also relates to a method for the preparation of said steroid compounds. The invention further relates to a pharmac...
|
|
WO/2004/055040A1 |
The present invention relates to a simple and new single pot process for the preparation of oryzanol from the oryzanol enriched saponifiable fraction of rice bran oil (RBO) soapstock.
|
|
WO/2004/046163A1 |
A method of separating ergosterol from an ergosterol solution in a water-insoluble organic solvent, characterized by supplying water to the solution to precipitate the ergosterol. By the method, ergosterol crystals can be obtained in a h...
|
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/029068A1 |
The present invention provides, in one aspect, novel derivatives comprising sterols and/or stanols and an NSAID selected from salicylic acids and arylalkanoic acids, including salts of these derivatives, and having one or more of the fol...
|
|
WO/2004/009527A1 |
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...
|
|
WO/2004/007521A2 |
The invention relates to compounds of formula (I), wherein R is ethyl, propyl or allyl, and to salts, solvates and pharmaceutically acceptable amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
|
|
WO/2004/000857A1 |
Under pressure, hydrogen gas is brought into contact with an organic compound capable of forming a hydrogen molecule compound, such as a hydrogen inclusion compound, in combination with hydrogen. Hydrogen can be stored stably in a relati...
|
|
WO/2004/001002A2 |
Compositions, methods, combinations, and kits for treating a disorder related to elevated serum cholesterol concentration, for example, atherosclerosis, elevated LDL plasma levels, low HDL plasma levels, hypertriglycendemia, hyperlipidem...
|
|
WO/2004/000869A1 |
This invention relates to novel compounds that are liver selective glucocorticoid receptor antagonists, to methods of preparing such compounds, and to methods for using such compounds in the regulation of metabolism, especially lowering ...
|
|
WO/2003/095470A1 |
A platinum complex having antitumor activity in which the metal ligands are dehydrocholic acid and a phosphine.
|
|
WO/2003/090547A1 |
A new composition for effecting serum cholesterol levels is claimed, said composition comprising (a) at least a waxy acid with 23 to 50 carbon atoms or derivatives thereof and with serum cholesterol level reducing properties, and (b) 0 t...
|
